Skip to content

Released Nov 9, 2020, before the open

10-Q filed Nov 9, 2020, 40 days after period end · 0001564590-20-052190

Q3 2020 · 10-Q
Revenue—
Net Income-$9.15MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.18N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$8,961,000N/M
Operating Cash Flowderived-$7,169,000N/M
Free Cash Flowderived-$7,176,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2020Q3 2019
Net Income-$9.15M-$8.55M
EPS Diluted-$0.18-$1.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR